STEALTH BIOTHERAPEUTICS CORP (MITO)

US85789A1051 - ADR

0.32  0 (-1.36%)

Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to MITO. MITO was compared to 612 industry peers in the Biotechnology industry. MITO has a bad profitability rating. Also its financial health evaluation is rather negative. MITO has a expensive valuation and it also scores bad on growth.



0

1. Profitability

1.1 Basic Checks

In the past year MITO has reported negative net income.
MITO had negative earnings in each of the past 5 years.
MITO had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

Industry RankSector Rank
ROA -143.5%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

MITO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

2

2. Health

2.1 Basic Checks

MITO has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, MITO has more shares outstanding
Compared to 1 year ago, MITO has a worse debt to assets ratio.

2.2 Solvency

A Debt/Equity ratio of -0.26 indicates that MITO is not too dependend on debt financing.
Industry RankSector Rank
Debt/Equity -0.26
Debt/FCF N/A
Altman-Z N/A
ROIC/WACCN/A
WACCN/A

2.3 Liquidity

MITO has a Current Ratio of 3.68. This indicates that MITO is financially healthy and has no problem in meeting its short term obligations.
A Quick Ratio of 3.68 indicates that MITO has no problem at all paying its short term obligations.
Industry RankSector Rank
Current Ratio 3.68
Quick Ratio 3.68

0

3. Growth

3.1 Past

MITO shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by 0.00%.
EPS 1Y0%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q0%
Revenue growth 1YN/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Revenue growth Q2QN/A

3.2 Future

The Earnings Per Share is expected to grow by 4.98% on average over the next years.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y23.5%
EPS Next 2Y16.73%
EPS Next 3Y7.29%
EPS Next 5Y4.98%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for MITO. In the last year negative earnings were reported.
Also next year MITO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA -0.07

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y16.73%
EPS Next 3Y7.29%

0

5. Dividend

5.1 Amount

MITO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

STEALTH BIOTHERAPEUTICS CORP

NASDAQ:MITO (11/15/2022, 7:00:01 PM)

0.32

0 (-1.36%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-18 2022-11-18/bmo
Earnings (Next)N/A N/A
Inst Owners0%
Inst Owner Change0%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap23.54M
Analysts82.86
Price Target1.81 (465.63%)
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)57.11%
Min EPS beat(2)50.98%
Max EPS beat(2)63.24%
EPS beat(4)3
Avg EPS beat(4)29.53%
Min EPS beat(4)-47.06%
Max EPS beat(4)63.24%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA -0.07
EPS(TTM)-0.08
EYN/A
EPS(NY)-0.05
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpSN/A
BVpS-0.71
TBVpS-0.07
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -143.5%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity -0.26
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Profit Quality N/A
Current Ratio 3.68
Quick Ratio 3.68
Altman-Z N/A
F-Score2
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)50.28%
Cap/Depr(5y)39.95%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
Growth
EPS 1Y0%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q0%
EPS Next Y23.5%
EPS Next 2Y16.73%
EPS Next 3Y7.29%
EPS Next 5Y4.98%
Revenue growth 1YN/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Revenue growth Q2QN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-8%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y15.94%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y16%
OCF growth 3YN/A
OCF growth 5YN/A